Cure Therapeutics


Cure Therapeutics (CT) is an advanced cell and gene therapeutics company with its proprietary platform technologies having board applications for currently incurable diseases such as non-responding cancers and liver metabolic disorders. CT has IPs for its unique immune-oncology approach of expanding and activating NK cell having higher cytotoxicity to tumors, delivering NK cell to various solid tumors and CAR-NK therapy while developing advanced cell therapeutics with liver derived cells for liver metabolic diseases such as OTC deficiency, NASH and hepatocirrhosis. After validation of promising in vivo efficacy, NK program is expected to enter into exploratory study for TNBC and HepaCell for OTC deficiency in 2020.